Because of the potential harm of discontinuation of ACE inhibitors and ARBs and lack of prospective clinical evidence, the international societies recommend continuing these medications in COVID-19 patients as well as the uninfected ones [56]. The gene discussed is ACE; the disease is COVID-19.